264 related articles for article (PubMed ID: 19053209)
21. New frontiers in cell-based immunotherapy of cancer.
D'Elios MM; Del Prete G; Amedei A
Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938
[TBL] [Abstract][Full Text] [Related]
22. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
23. Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.
Wang HY; Wang RF
Adv Immunol; 2012; 114():151-76. PubMed ID: 22449781
[TBL] [Abstract][Full Text] [Related]
24. Current status and future prospects of peptide-based cancer vaccines.
Wada S; Yada E; Ohtake J; Fujimoto Y; Uchiyama H; Yoshida S; Sasada T
Immunotherapy; 2016 Nov; 8(11):1321-1333. PubMed ID: 27993087
[TBL] [Abstract][Full Text] [Related]
25. [New biotechnologic products in treatment and prevention].
Kvale D; Jahnsen T
Tidsskr Nor Laegeforen; 1989 Nov; 109(33):3427-30. PubMed ID: 2609304
[TBL] [Abstract][Full Text] [Related]
26. Peptide-based vaccines for cancer therapy.
Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
[TBL] [Abstract][Full Text] [Related]
27. Peptide-based vaccines for cancer immunotherapy.
Brinkman JA; Fausch SC; Weber JS; Kast WM
Expert Opin Biol Ther; 2004 Feb; 4(2):181-98. PubMed ID: 14998777
[TBL] [Abstract][Full Text] [Related]
28. Composite peptide-based vaccines for cancer immunotherapy (Review).
Yang J; Zhang Q; Li K; Yin H; Zheng JN
Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
[TBL] [Abstract][Full Text] [Related]
29. Peptide vaccine.
Izumoto S
Adv Exp Med Biol; 2012; 746():166-77. PubMed ID: 22639167
[TBL] [Abstract][Full Text] [Related]
30. Current status of immunotherapy for the treatment of biliary tract cancer.
Takahashi R; Yoshitomi M; Yutani S; Shirahama T; Noguchi M; Yamada A; Itoh K; Sasada T
Hum Vaccin Immunother; 2013 May; 9(5):1069-72. PubMed ID: 23376808
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook.
Mikszta JA; Laurent PE
Expert Rev Vaccines; 2008 Nov; 7(9):1329-39. PubMed ID: 18980537
[TBL] [Abstract][Full Text] [Related]
32. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
33. Colorectal cancer vaccines: Tumor-associated antigens
Wagner S; Mullins CS; Linnebacher M
World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371
[TBL] [Abstract][Full Text] [Related]
34. Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome.
Voskens CJ; Strome SE; Sewell DA
Curr Mol Med; 2009 Aug; 9(6):683-93. PubMed ID: 19689295
[TBL] [Abstract][Full Text] [Related]
35. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
[TBL] [Abstract][Full Text] [Related]
36. Improving the efficacy of peptide vaccines in cancer immunotherapy.
Zahedipour F; Jamialahmadi K; Zamani P; Reza Jaafari M
Int Immunopharmacol; 2023 Oct; 123():110721. PubMed ID: 37543011
[TBL] [Abstract][Full Text] [Related]
37. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
[TBL] [Abstract][Full Text] [Related]
38. Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides.
Smith KA; Tam VL; Wong RM; Pagarigan RR; Meisenburg BL; Joea DK; Liu X; Sanders C; Diamond D; Kündig TM; Qiu Z; Bot A
Vaccine; 2009 Apr; 27(19):2603-15. PubMed ID: 19428867
[TBL] [Abstract][Full Text] [Related]
39. Getting peptide vaccines to work: just a matter of quality control?
Celis E
J Clin Invest; 2002 Dec; 110(12):1765-8. PubMed ID: 12488425
[No Abstract] [Full Text] [Related]
40. Personalized peptide vaccines and their relation to other therapies in urological cancer.
Kimura T; Egawa S; Uemura H
Nat Rev Urol; 2017 Aug; 14(8):501-510. PubMed ID: 28561807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
